APHEXDA
GrowthPeptidemotixafortide
NDASUBCUTANEOUSPOWDER
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
APHEXDA (motixafortide) is c-x-c motif chemokine receptor 4 (cxcr4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (sdf-1α)/c-x-c motif chemokine ligand 12 (cxcl12). First approved in 2023.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APHEXDA (motixafortide) is a CXCR4 antagonist administered subcutaneously as a powder for reconstitution that mobilizes hematopoietic stem and progenitor cells from bone marrow into peripheral circulation. It blocks CXCR4–SDF-1α interactions to overcome the homing mechanisms that anchor stem cells in the marrow microenvironment. The drug enables improved stem cell collection for transplantation procedures by increasing circulating stem cell yields.
Growth15.5 years to LOE
Early-stage product in growth phase with no direct competitors currently creates opportunities for market definition and team expansion within commercial and medical affairs functions.
Mechanism of Action
C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (SDF-1α)/C-X-C Motif Chemokine Ligand 12 (CXCL12). SDF-1α and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells to the marrow compartment. Once in the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Motixafortide for MRD Sensitization in AML
Started May 2026
10 enrolled
Acute Myeloid LeukemiaMeasurable Residual Disease
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Started Dec 2025
60 enrolled
Multiple Myeloma
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Started Sep 2025
94 enrolled
Multiple Myeloma
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Started Oct 2024
20 enrolled
Multiple Myeloma
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Started Jul 2023
10 enrolled
Sickle Cell Disease
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.